JP2008545700A - ４−（ビフェニリル）アゼチジン−２−オンホスホン酸類の製造方法 - Google Patents

４−（ビフェニリル）アゼチジン−２−オンホスホン酸類の製造方法 Download PDF

Info

Publication number
JP2008545700A
JP2008545700A JP2008513703A JP2008513703A JP2008545700A JP 2008545700 A JP2008545700 A JP 2008545700A JP 2008513703 A JP2008513703 A JP 2008513703A JP 2008513703 A JP2008513703 A JP 2008513703A JP 2008545700 A JP2008545700 A JP 2008545700A
Authority
JP
Japan
Prior art keywords
group
ether
formula
groups
ether groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008513703A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008545700A5 (enExample
Inventor
ステファン アントネッリ
ティモシー シー． バーデン
ピーター リー
エデュアルド マルティネス
ウェイン シー． シェイラー
ジョン ジェー． タレー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Microbia Inc
Original Assignee
Microbia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microbia Inc filed Critical Microbia Inc
Publication of JP2008545700A publication Critical patent/JP2008545700A/ja
Publication of JP2008545700A5 publication Critical patent/JP2008545700A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
    • C07C251/04—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C251/10—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton
    • C07C251/16—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
    • C07C251/24—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/26—Oxygen atoms attached in position 2 with hetero atoms or acyl radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/38—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C07F7/1872—Preparation; Treatments not provided for in C07F7/20
    • C07F7/1892—Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/568—Four-membered rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
JP2008513703A 2005-05-25 2006-05-25 ４−（ビフェニリル）アゼチジン−２−オンホスホン酸類の製造方法 Pending JP2008545700A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68448105P 2005-05-25 2005-05-25
PCT/US2006/020226 WO2006127893A2 (en) 2005-05-25 2006-05-25 Processes for production of 4-(biphenylyl)azetidin-2-one phosphonic acids

Publications (2)

Publication Number Publication Date
JP2008545700A true JP2008545700A (ja) 2008-12-18
JP2008545700A5 JP2008545700A5 (enExample) 2009-07-30

Family

ID=37103301

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008513703A Pending JP2008545700A (ja) 2005-05-25 2006-05-25 ４−（ビフェニリル）アゼチジン−２−オンホスホン酸類の製造方法

Country Status (15)

Country Link
US (1) US20090099355A1 (enExample)
EP (1) EP1896135A2 (enExample)
JP (1) JP2008545700A (enExample)
KR (1) KR20080025077A (enExample)
CN (1) CN101222950A (enExample)
AU (1) AU2006249905A1 (enExample)
BR (1) BRPI0611415A2 (enExample)
CA (1) CA2609506A1 (enExample)
EA (1) EA200702614A1 (enExample)
IL (1) IL187626A0 (enExample)
MA (1) MA29553B1 (enExample)
NO (1) NO20076597L (enExample)
TW (1) TW200801027A (enExample)
WO (1) WO2006127893A2 (enExample)
ZA (1) ZA200710857B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018104447A (ja) * 2011-12-30 2018-07-05 ダウ アグロサイエンシィズ エルエルシー ４−クロロ−２−フルオロ−３−置換−フェニルボロン酸ピナコールエステルの形成方法およびその使用方法

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
DE602004008100T2 (de) * 2003-11-10 2008-04-30 Microbia Inc., Cambridge 4-biarylyl-1-phenylazetidin-2-one
ATE485267T1 (de) 2003-12-23 2010-11-15 Astrazeneca Ab Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung
US20060135755A1 (en) 2004-12-20 2006-06-22 Schering Corporation Process for the synthesis of azetidinones
UY29607A1 (es) 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
AR057072A1 (es) 2005-06-22 2007-11-14 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
DE102005055726A1 (de) * 2005-11-23 2007-08-30 Sanofi-Aventis Deutschland Gmbh Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
AR060623A1 (es) 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
WO2008061238A2 (en) * 2006-11-16 2008-05-22 Ironwood Pharmaceuticals, Inc. Processes for production of 4-biphenylyazetidin-2-ones
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
WO2009157019A2 (en) * 2008-06-23 2009-12-30 Ind-Swift Laboratories Limited Process for preparing ezetimibe using novel allyl intermediates
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
SG178880A1 (en) 2009-08-26 2012-04-27 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
CN102285932B (zh) * 2011-09-01 2013-06-12 浙江大学 一种依替米贝中间体的制备方法
CN103396429B (zh) * 2013-06-28 2016-05-25 杭州师范大学 一种硅手性中心的硅烷衍生物
BR112021002207A2 (pt) 2018-08-10 2021-05-04 Diapin Therapeutics, Llc tri-peptídeos e tratamento de distúrbios metabólicos, cardiovasculares e inflamatórios
CN111825653A (zh) * 2019-04-19 2020-10-27 安道麦马克西姆有限公司 取代吡唑类化合物的制备及其作为邻氨基苯甲酰胺前体的用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06508637A (ja) * 1991-07-23 1994-09-29 シェリング・コーポレーション 血清コレステロール低下薬として有用な置換β−ラクタム化合物およびそれらの製法
WO2002066464A1 (fr) * 2001-02-23 2002-08-29 Kotobuki Pharmaceutical Co., Ltd. Composes de beta-lactame, leur procede de production et agents d'abaissement du taux de cholesterol contenant ces composes
JP2004516280A (ja) * 2000-12-21 2004-06-03 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 新規な１，２−ジフェニルアゼチジノン、その調製方法、その化合物を含む薬剤、および脂質代謝障害を治療するためのその使用
JP2005053931A (ja) * 1998-12-07 2005-03-03 Schering Plough Corp アゼチジノンの合成プロセス
JP2008540557A (ja) * 2005-05-11 2008-11-20 マイクロビア インコーポレーテッド フェノール型４−ビフェニリルアゼチジン−２−オンの製造方法
JP2008542205A (ja) * 2005-05-06 2008-11-27 マイクロビア インコーポレーテッド ４−ビフェニリルアゼチジン−２−オンの製造方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
CA2158191A1 (en) * 1994-09-16 1996-03-17 Junji Yokoi Method for preventing settlement of aquatic fouling organisms
US6207822B1 (en) * 1998-12-07 2001-03-27 Schering Corporation Process for the synthesis of azetidinones
IL156552A0 (en) * 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
BRPI0208384B1 (pt) * 2001-03-28 2016-05-31 Merck Sharp & Dohme síntese enantiosseletiva de compostos intermediários de azetidinona
WO2004099132A2 (en) * 2003-05-05 2004-11-18 Ranbaxy Laboratories Limited Process for the preparation of trans-isomers of diphenylazetidinone derivatives
DE602004008100T2 (de) * 2003-11-10 2008-04-30 Microbia Inc., Cambridge 4-biarylyl-1-phenylazetidin-2-one
EP1851197A2 (en) * 2005-02-09 2007-11-07 Microbia, Inc. Phenylazetidinone derivatives

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06508637A (ja) * 1991-07-23 1994-09-29 シェリング・コーポレーション 血清コレステロール低下薬として有用な置換β−ラクタム化合物およびそれらの製法
JP2005053931A (ja) * 1998-12-07 2005-03-03 Schering Plough Corp アゼチジノンの合成プロセス
JP2004516280A (ja) * 2000-12-21 2004-06-03 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 新規な１，２−ジフェニルアゼチジノン、その調製方法、その化合物を含む薬剤、および脂質代謝障害を治療するためのその使用
WO2002066464A1 (fr) * 2001-02-23 2002-08-29 Kotobuki Pharmaceutical Co., Ltd. Composes de beta-lactame, leur procede de production et agents d'abaissement du taux de cholesterol contenant ces composes
JP2008542205A (ja) * 2005-05-06 2008-11-27 マイクロビア インコーポレーテッド ４−ビフェニリルアゼチジン−２−オンの製造方法
JP2008540557A (ja) * 2005-05-11 2008-11-20 マイクロビア インコーポレーテッド フェノール型４−ビフェニリルアゼチジン−２−オンの製造方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6012022029; ＣＬＡＤＥＲ，Ｊ．Ｗ．　ｅｔ　ａｌ: '２-Ａｚｅｔｉｄｉｎｏｎｅ　Ｃｈｏｌｅｓｔｅｒｏｌ　Ａｂｓｏｒｐｔｉｏｎ　Ｉｎｈｉｂｉｔｏｒｓ：　Ｓｔｒｕｃｔｕｒｅ-Ａｃｔｉｖｉｔｙ　Ｒｅｌａｔｉｏｎｓｈｉｐｓ　ｏｎ　ｔｈｅ　Ｈｅｔｅｒｏｃｙｃｌｉ' Ｊｏｕｒｎａｌ　ｏｆ　Ｍｅｄｉｃｉｎａｌ　Ｃｈｅｍｉｓｔｒｙ Ｖｏｌ．３９，　Ｎｏ．１９, 1996, ｐ．３６８４-３６９３ *
JPN6012022032; ＶＡＣＣＡＲＯ，Ｗ．Ｄ．　ｅｔ　ａｌ: '２-ａｚｅｔｉｄｉｎｏｎｅ　ｃｈｏｌｅｓｔｅｒｏｌ　ａｂｓｏｒｐｔｉｏｎ　ｉｎｈｉｂｉｔｏｒｓ：　ｉｎｃｒｅａｓｅｄ　ｐｏｔｅｎｃｙ　ｂｙ　ｓｕｂｓｔｉｔｕｔｉｏｎ　ｏｆ　ｔｈｅ　Ｃ-４　ｐｈｅｎｙｌ' Ｂｉｏｏｒｇａｎｉｃ　＆　Ｍｅｄｉｃｉｎａｌ　Ｃｈｅｍｉｓｔｒｙ Ｖｏｌ．６，　Ｎｏ．９, 1998, ｐ．１４２９-１４３７ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018104447A (ja) * 2011-12-30 2018-07-05 ダウ アグロサイエンシィズ エルエルシー ４−クロロ−２−フルオロ−３−置換−フェニルボロン酸ピナコールエステルの形成方法およびその使用方法

Also Published As

Publication number Publication date
CA2609506A1 (en) 2006-11-30
WO2006127893A3 (en) 2007-03-08
KR20080025077A (ko) 2008-03-19
MA29553B1 (fr) 2008-06-02
IL187626A0 (en) 2008-03-20
EA200702614A1 (ru) 2008-04-28
TW200801027A (en) 2008-01-01
US20090099355A1 (en) 2009-04-16
ZA200710857B (en) 2008-12-31
AU2006249905A1 (en) 2006-11-30
EP1896135A2 (en) 2008-03-12
CN101222950A (zh) 2008-07-16
BRPI0611415A2 (pt) 2010-09-08
WO2006127893A2 (en) 2006-11-30
NO20076597L (no) 2008-01-18

Similar Documents

Publication Publication Date Title
US20090099355A1 (en) Processes for Production of 4-(Biphenylyl)Azetidin-2-One Phosphonic Acids
JP2008540557A (ja) フェノール型４−ビフェニリルアゼチジン−２−オンの製造方法
CA2438961C (en) Beta-lactam compounds, manufacturing methods of the compounds and serum hypocholesterolemic agents containing the compounds
KR101156588B1 (ko) 에제티밉의 제조방법 및 이에 사용되는 중간체
WO2003042180A9 (en) Process for producing optically active oxoheptenoic acid ester
JPH08508281A (ja) β−フェニルイソセリン誘導体の製造法
KR20040084915A (ko) 신규의 보로네이트 에스테르
KR20080011687A (ko) 4-비페닐일아제티딘-2-온의 제조방법
US7550608B2 (en) Processes for the preparation of docetaxel
US20100228038A1 (en) Processes for the production of polycyclic fused ring compounds
CN101213170A (zh) 制备4-联苯基氮杂环丁烷-2-酮化合物的方法
US6335458B1 (en) Intermediate compounds in the synthesis of the A ring moiety of 2-substituted vitamin D derivatives
US5973161A (en) Enantioselective synthesis of cyclopentenes
KR100201564B1 (ko) 아제티디논 화합물 및 그 제조방법
WO2008061238A2 (en) Processes for production of 4-biphenylyazetidin-2-ones
JPWO1999043641A1 (ja) ２位に置換基を有するビタミンｄ誘導体のａ環部分の合成中間体化合物
JP2004518685A (ja) クロマニル安息香酸の調製方法
JPS643188B2 (enExample)
JPH09241266A (ja) ビス−テトラヒドロフラン誘導体の製造方法
JP2002114749A (ja) 光学活性２−ヒドロキシ−３−フェニルプロピオニトリル誘導体の製造法
JP2000256368A (ja) 光学活性なオキサザボロリジン類、その製造方法および用途
JPH0788354B2 (ja) キラルな４−アリールオキシアゼチジノンの改良された製造方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090508

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090610

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120501

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121030